Companies: 10,795·Total market cap: $144.5T
Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

RLMDNASDAQHealthcare● Active
$5.72
$-0.23(-3.87%)
Market Cap$419468318
P/E Ratio—
52W High$8
52W Low$0.52
SEC Filings

Relmada Therapeutics, Inc. (RLMD) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001553643 · RLMD · NASDAQ · as of Jun 9, 2026

Filing snapshot

595
Total Filings
8-K
Latest Form
2026-05-28
Most Recent
2014
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001553643 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-19
Fiscal Year End
Mar 19, 2026
Accession No.
0001213900-26-031862
Primary Document
ea0273255-10k_relmada.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001553643 · Accession 0001213900-26-031862

Latest Key Filings

10-QQuarterly Report
QUARTERLY REPORT
2026-05-12
View 10-Q on SEC
8-KCurrent Report
CURRENT REPORT
2026-05-28Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
CURRENT REPORT
2026-05-28
View
S-3ASRS-3ASR
REGISTRATION STATEMENT
2026-05-13
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-13
View
8-KCurrent Report
CURRENT REPORT
2026-05-12
View
10-QQuarterly Report
QUARTERLY REPORT
2026-05-12
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-04
View
DEFA14AProxy Statement (Additional)
DEFINITIVE ADDITIONAL MATERIALS
2026-04-17
View
DEF 14AProxy Statement
PROXY STATEMENT
2026-04-17
View
EFFECTEFFECT
EFFECT
2026-04-09
View
424B3424B3
PROSPECTUS
2026-04-09
View
CORRESPCORRESP
CORRESP
2026-04-07
View
UPLOADUPLOAD
UPLOAD
2026-04-07
View
PRE 14APRE 14A
PROXY STATEMENT
2026-04-06
View
S-3Shelf Registration
REGISTRATION STATEMENT
2026-04-03
View
8-KCurrent Report
CURRENT REPORT
2026-03-20
View
Showing 1–15 of 418 filingsForm 4 / 144 hidden· 595 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001553643  |  Exchange: NASDAQ · Healthcare

Relmada Therapeutics, Inc. (NASDAQ: RLMD) has submitted 595 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2014. As a Healthcare sector company with CIK 0001553643, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Relmada Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Relmada Therapeutics, Inc. 10-K was filed on 2026-03-19 for fiscal year ending 2026. Historical RLMD 10-K annual reports are available from 2012 through 2026.

Investors researching Relmada Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
VXRT SEC Filings →IMUX SEC Filings →RPTX SEC Filings →FBIO SEC Filings →ACET SEC Filings →TCRX SEC Filings →PMVP SEC Filings →CBUS SEC Filings →
→ RLMD Financials→ RLMD Earnings→ RLMD Insider Trades

Frequently Asked Questions

RLMD SEC Filings · 8 questions

Relmada Therapeutics, Inc. (RLMD) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 595 filings and access original documents at no cost. Relmada Therapeutics, Inc.'s CIK is 0001553643.

RLMD SEC filingsRelmada Therapeutics, Inc. SEC documentsfind RLMD 10-K